Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, we wish to inform you that Board of Directors of the Company, at its meeting held today, on July 04, 2025 has considered and approved the following: 1. Allotment of 60,00,000 Equity Shares upon Conversion of Warrants to the member of promoter group on Preferential basis. The requisite disclosures are set out in Annexure A to this letter. We hereby submit that the Board Meeting had commenced at 02:00 PM and concluded at 02.40 PM.This intimation is also uploaded on the Company website: www.gennexlab.comWe request you to take the above information on record and acknowledge the receipt of the same.
Gennex Laboratories Limited Press Release Jul 04 2025
Filed with BSE · · 3 pages · English
Release
Gennex Laboratories Limited on 6ix
Earlier from Gennex Laboratories
- Gennex Laboratories Limited Press Release Jun 23 2025
- Gennex Laboratories Limited Press Release Jun 04 2025
- Gennex Laboratories Limited Press Release Jun 02 2025
- Gennex Laboratories Limited Press Release May 30 2025
- Gennex Laboratories Limited Press Release May 22 2025
Later from Gennex Laboratories
- Gennex Laboratories Limited Press Release Jul 07 2025
- Gennex Laboratories Limited Press Release Jul 08 2025
- Gennex Laboratories Limited Press Release Jul 14 2025
- Gennex Laboratories Limited Press Release Jul 24 2025
- Gennex Laboratories Limited Press Release Jul 28 2025
Follow Gennex Laboratories into a list and get an email when it puts out news.
Follow Gennex Laboratories